A dimerized single-chain variable fragment system for the assessment of neutralizing activity of phage display-selected antibody fragments specific for cytomegalovirus

Journal of Immunological Methods

Volumn 376, Issue 1-2, 2012, Pages 69-78

  Carlsson, Fredrika ^a   Trilling, Mirko ^b   Perez, Franck ^c   Ohlin, Mats ^a  

^a LUND UNIVERSITY   (Sweden)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c INSTITUT CURIE   (France)

Author keywords

Cytomegalovirus; Fc fusion protein; High throughput; Monoclonal antibodies; Phage display; Virus neutralization

Indexed keywords

ANTIGEN; CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; BIOLOGICAL ACTIVITY; CYTOMEGALOVIRUS; HIGH THROUGHPUT SCREENING; NONHUMAN; PASSIVE IMMUNIZATION; PHAGE DISPLAY; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLONING, MOLECULAR; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HUMANS; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

CYTOMEGALOVIRUS;

EID: 84856556889     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.11.010     Document Type: Article

References (37)

1. Andreoni M., Faircloth M., Vugler L., Britt W.J. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 1989, 23:157.
2. Axelsson F., Persson J., Moreau E., Côte M.H., Lamarre A., Ohlin M. Novel antibody specificities targeting glycoprotein B of cytomegalovirus identified by molecular library technology. N. Biotechnol. 2009, 25:429.
3. Barbas C.F., Burton D.R. Selection and evolution of high-affinity human anti-viral antibodies. Trends Biotechnol. 1996, 14:230.
4. Barrios Y., Knör S., Lantto J., Mach M., Ohlin M. Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties. Mol. Immunol. 2007, 44:680.
5. Burton D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2002, 2:706.
6. Burton D.R., Williamson R.A., Parren P.W. Antibody and virus: binding and neutralization. Virology 2000, 270:1.
7. Furebring C., Speckner A., Mach M., Sandlie I., Norderhaug L., Borrebaeck C.A.K., Turesson H., Ohlin M. Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region. Mol. Immunol. 2002, 38:833.
8. Gerna G., Sarasini A., Patrone M., Percivalle E., Fiorina L., Campanini G., Gallina A., Baldanti F., Revello M.G. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol. 2008, 89:853.
9. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., Davenport A., Jones G., Wheeler D.C., O'Beirne J., Thorburn D., Patch D., Atkinson C.E., Pichon S., Sweny P., Lanzman M., Woodford E., Rothwell E., Old N., Kinyanjui R., Haque T., Atabani S., Luck S., Prideaux S., Milne R.S., Emery V.C., Burroughs A.K. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256.
10. Hallborn J., Carlsson R. Automated screening procedure for high-throughput generation of antibody fragments. Biotechniques Suppl 2002, 30.
11. Hansen S.G., Powers C.J., Richards R., Ventura A.B., Ford J.C., Siess D., Axthelm M.K., Nelson J.A., Jarvis M.A., Picker L.J., Fruh K. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 2010, 328:102.
12. Hengel H., Esslinger C., Pool J., Goulmy E., Koszinowski U.H. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. J. Gen. Virol. 1995, 76(Pt 12):2987.
13. Hust M., Meyer T., Voedisch B., Rulker T., Thie H., El-Ghezal A., Kirsch M.I., Schutte M., Helmsing S., Meier D., Schirrmann T., Dübel S. A human scFv antibody generation pipeline for proteome research. J. Biotechnol. 2011, 152:159.
14. Jonjic S., Pavic I., Polic B., Crnkovic I., Lucin P., Koszinowski U.H. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 1994, 179:1713.
15. Klenovsek K., Weisel F., Schneider A., Appelt U., Jonjic S., Messerle M., Bradel-Tretheway B., Winkler T.H., Mach M. Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 2007, 110:3472.
16. Krawczyk A., Krauss J., Eis-Hubinger A.M., Daumer M.P., Schwarzenbacher R., Dittmer U., Schneweis K.E., Jager D., Roggendorf M., Arndt M.A. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J. Virol. 2011, 85:1793.
17. Lantto J., Fletcher J.M., Ohlin M. A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B. J. Gen. Virol. 2002, 83:2001.
18. Lantto J., Lindroth Y., Ohlin M. Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomegalovirus. Eur. J. Immunol. 2002, 32:1659.
19. Lantto J., Fletcher J.M., Ohlin M. Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus. Virology 2003, 305:201.
20. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., Gerna G., Sallusto F., Lanzavecchia A. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 2010, 84:1005.
21. McLean G.R., Olsen O.A., Watt I.N., Rathanaswami P., Leslie K.B., Babcook J.S., Schrader J.W. Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. J. Immunol. 2005, 174:4768.
22. Moutel S., El Marjou A., Vielemeyer O., Nizak C., Benaroch P., Dubel S., Perez F. A multi-Fc-species system for recombinant antibody production. BMC Biotechnol. 2009, 9:14.
23. Nigro G., Adler S.P. Cytomegalovirus infections during pregnancy. Curr. Opin. Obstet. Gynecol. 2010, 23:123.
24. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 2005, 353:1350.
25. Ohlin M., Sundqvist V.A., Mach M., Wahren B., Borrebaeck C.A.K. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J. Virol. 1993, 67:703.
26. Pötzsch S., Spindler N., Wiegers A.K., Fisch T., Rucker P., Sticht H., Grieb N., Baroti T., Weisel F., Stamminger T., Martin-Parras L., Mach M., Winkler T.H. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 2011, 7:e1002172.
27. Reinhard H., Le V.T., Ohlin M., Hengel H., Trilling M. Exploitation of herpesviral transactivation allows quantitative reporter gene-based assessment of virus entry and neutralization. PLoS One 2011, 6:e14532.
28. Schoppel K., Hassfurther E., Britt W., Ohlin M., Borrebaeck C.A., Mach M. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 1996, 216:133.
29. Sinzger C., Hahn G., Digel M., Katona R., Sampaio K.L., Messerle M., Hengel H., Koszinowski U., Brune W., Adler B. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 2008, 89:359.
30. Slavuljica I., Busche A., Babic M., Mitrovic M., Gasparovic I., Cekinovic D., Markova Car E., Pernjak Pugel E., Cikovic A., Lisnic V.J., Britt W.J., Koszinowski U., Messerle M., Krmpotic A., Jonjic S. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J. Clin. Invest. 2010, 120:4532.
31. Slootstra J.W., Kuperus D., Plückthun A., Meloen R.H. Identification of new tag sequences with differential and selective recognition properties for the anti-FLAG monoclonal antibodies M1, M2 and M5. Mol. Divers. 1997, 2:156.
32. Spaete R.R. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant. Proc. 1991, 23:90.
33. Spaete R.R., Gehrz R.C., Landini M.P. Human cytomegalovirus structural proteins. J. Gen. Virol. 1994, 75:3287.
34. Speckner A., Glykofrydes D., Ohlin M., Mach M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J. Gen. Virol. 1999, 80(Pt 8):2183.
35. Stratton K.R., Durch J.S., Lawrence R.S. Vaccines for the 21st Century. A Tool for Decision-making 2001, 165. National Academy Press, Washington D.C.
36. Turunen L., Takkinen K., Söderlund H., Pulli T. Automated panning and screening procedure on microplates for antibody generation from phage display libraries. J. Biomol. Screen. 2009, 14:282.
37. Yoo E.M., Wims L.A., Chan L.A., Morrison S.L. Human IgG2 can form covalent dimers. J. Immunol. 2003, 170:3134.